Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death

Biochemical and Biophysical Research Communications

Volumn 411, Issue 2, 2011, Pages 421-426

  Singh, Krishna K ^a   Shukla, Praphulla C ^a   Quan, Adrian ^a   Lovren, Fina ^a   Pan, Yi ^a   Wolfstadt, Jesse I ^a   Gupta, Milan ^a,c   Al Omran, Mohammed ^b   Leong Poi, Howard ^a   Teoh, Hwee ^a,c   Verma, Subodh ^a,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Canadian Cardiovascular Research Network   (Canada)

Author keywords

Apoptosis; Cardiomyocyte; ERBB2; Herceptin; Trastuzumab

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN MDM2; PROTEIN P53; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; HEART DEATH; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; HEART; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

RATTUS;

EID: 79960841298     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.169     Document Type: Article

References (55)

1. Coussens L., Yang-Feng T.L., Liao Y.C., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230:1132-1139.
2. Schechter A.L., Stern D.F., Vaidyanathan L., et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312:513-516.
3. Semba K., Kamata N., Toyoshima K., et al. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. USA 1985, 82:6497-6501.
4. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
5. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
6. Liu E., Thor A., He M., et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992, 7:1027-1032.
7. Park K., Han S., Kim H.J., et al. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006, 48:702-707.
8. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl. 2):1-13.
9. Gonzalez-Angulo A.M., Litton J.K., Broglio K.R., et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1cm or smaller. J. Clin. Oncol. 2009, 27:5700-5706.
10. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14:737-744.
11. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17:2639-2648.
12. Pegram M.D., Lipton A., Hayes D.F., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 1998, 16:2659-2671.
13. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 2005, 23:4265-4274.
14. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
15. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006, 354:809-820.
16. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
17. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
18. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
19. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 2002, 20:1215-1221.
20. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001, 61(Suppl. 2):58-66.
21. Lee K.F., Simon H., Chen H., et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378:394-398.
22. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 2002, 8:459-465.
23. Ozcelik C., Erdmann B., Pilz B., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA 2002, 99:8880-8885.
24. Pugatsch T., Abedat S., Lotan C., et al. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res. 2006, 8:R35.
25. Fujimoto-Ouchi K., Sekiguchi F., Yamamoto K., et al. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy. Cancer Chemother. Pharmacol. 2010, 66:269-276.
26. Guan H., Jia S.F., Zhou Z., et al. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin. Cancer Res. 2005, 11:2008-2017.
27. Parker T.G., Packer S.E., Schneider M.D. Peptide growth factors can provoke " fetal" contractile protein gene expression in rat cardiac myocytes. J. Clin. Invest. 1990, 85:507-514.
28. Komarov P.G., Komarova E.A., Kondratov R.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
29. Zhao Y.Y., Sawyer D.R., Baliga R.R., et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. 1998, 273:10261-10269.
30. Ng R., Better N., Green M.D. Anticancer agents and cardiotoxicity. Semin. Oncol. 2006, 33:2-14.
31. Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. USA 1990, 87:2569-2573.
32. Schneider J.W., Chang A.Y., Rocco T.P. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin. Oncol. 2001, 28:18-26.
33. Perik P.J., de Vries E.G., Gietema J.A., et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur. J. Heart Fail. 2007, 9:173-177.
34. Riccio G., Esposito G., Leoncini E., et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J. 2009, 23:3171-3178.
35. Jassal D.S., Han S.Y., Hans C., et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J. Am. Soc. Echocardiogr. 2009, 22:418-424.
36. Grazette L.P., Boecker W., Matsui T., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 2004, 44:2231-2238.
37. Gordon L.I., Burke M.A., Singh A.T., et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J. Biol. Chem. 2009, 284:2080-2087.
38. Vazquez A., Bond E.E., Levine A.J., et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 2008, 7:979-987.
39. Momand J., Zambetti G.P., Olson D.C., et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
40. Jones S.N., Roe A.E., Donehower L.A., et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
41. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378:203-206.
42. Cuello M., Ettenberg S.A., Clark A.S., et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61:4892-4900.
43. Longva K.E., Pedersen N.M., Haslekas C., et al. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer 2005, 116:359-367.
44. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
45. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001, 2:127-137.
46. Matsui T., Tao J., del Monte F., et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001, 104:330-335.
47. Condorelli G., Drusco A., Stassi G., et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99:12333-12338.
48. Fujio Y., Nguyen T., Wencker D., et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000, 101:660-667.
49. Shiraishi I., Melendez J., Ahn Y., et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 2004, 94:884-891.
50. Skurk C., Izumiya Y., Maatz H., et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J. Biol. Chem. 2005, 280:20814-20823.
51. Zhou B.P., Liao Y., Xia W., et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 2001, 3:973-982.
52. Pentassuglia L., Timolati F., Seifriz F., et al. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp. Cell Res. 2007, 313:1588-1601.
53. Sawyer D.B., Zuppinger C., Miller T.A., et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002, 105:1551-1554.
54. Lewis Phillips G.D., Li G., Dugger D.L., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68:9280-9290.
55. Araki S., Eitel J.A., Batuello C.N., et al. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J. Clin. Invest. 2010, 120:290-302.